CytoMed Therapeutics (GDTC) Competitors

$1.13 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.15 +0.02 (+1.77%)

As of 05/22/2026 07:18 PM Eastern

GDTC vs. INMB, ELUT, ATOS, TELO, and LITS

Should you buy CytoMed Therapeutics stock or one of its competitors? MarketBeat compares CytoMed Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CytoMed Therapeutics include INmune Bio (INMB), Elutia (ELUT), Atossa Genetics (ATOS), Telomir Pharmaceuticals (TELO), and Lite Strategy (LITS). These companies are all part of the "pharmaceutical products" industry.

How does CytoMed Therapeutics compare to INmune Bio?

CytoMed Therapeutics (NASDAQ:GDTC) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

INmune Bio has a consensus target price of $8.00, suggesting a potential upside of 451.72%. Given INmune Bio's stronger consensus rating and higher probable upside, analysts plainly believe INmune Bio is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 21.0% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, INmune Bio had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 2 mentions for INmune Bio and 1 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 0.75 beat INmune Bio's score of 0.30 indicating that CytoMed Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
INmune Bio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytoMed Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the broader market. Comparatively, INmune Bio has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

CytoMed Therapeutics has higher revenue and earnings than INmune Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoMed Therapeutics	$250K	53.47	-$3.10M	N/A	N/A
INmune Bio	$50K	770.82	-$45.93M	-$1.67	N/A

CytoMed Therapeutics' return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytoMed Therapeutics	N/A	N/A	N/A
INmune Bio	N/A	-103.03%	-77.66%

Summary

INmune Bio beats CytoMed Therapeutics on 9 of the 14 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Elutia?

CytoMed Therapeutics (NASDAQ:GDTC) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, CytoMed Therapeutics had 1 more articles in the media than Elutia. MarketBeat recorded 1 mentions for CytoMed Therapeutics and 0 mentions for Elutia. CytoMed Therapeutics' average media sentiment score of 0.75 beat Elutia's score of 0.00 indicating that CytoMed Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CytoMed Therapeutics	Positive
Elutia	Neutral

0.0% of CytoMed Therapeutics shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 27.6% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Elutia has a consensus price target of $6.00, suggesting a potential upside of 417.24%. Given Elutia's stronger consensus rating and higher probable upside, analysts clearly believe Elutia is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Elutia has higher revenue and earnings than CytoMed Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoMed Therapeutics	$250K	53.47	-$3.10M	N/A	N/A
Elutia	$12.29M	4.04	$53.38M	$0.86	1.35

Elutia has a net margin of 312.09% compared to CytoMed Therapeutics' net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
CytoMed Therapeutics	N/A	N/A	N/A
Elutia	312.09%	N/A	-53.97%

CytoMed Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market. Comparatively, Elutia has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Summary

Elutia beats CytoMed Therapeutics on 9 of the 13 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Atossa Genetics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the broader market.

Atossa Genetics presently has a consensus target price of $36.33, suggesting a potential upside of 632.53%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Atossa Genetics is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CytoMed Therapeutics has higher revenue and earnings than Atossa Genetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
CytoMed Therapeutics	$250K	53.47	-$3.10M	N/A	N/A

In the previous week, Atossa Genetics had 2 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 3 mentions for Atossa Genetics and 1 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 0.75 beat Atossa Genetics' score of -0.74 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CytoMed Therapeutics' return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
CytoMed Therapeutics	N/A	N/A	N/A

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Atossa Genetics beats CytoMed Therapeutics on 8 of the 13 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 2 mentions for Telomir Pharmaceuticals and 1 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 0.75 beat Telomir Pharmaceuticals' score of 0.71 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telomir Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telomir Pharmaceuticals has a beta of -0.21, indicating that its stock price is 121% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market.

CytoMed Therapeutics has higher revenue and earnings than Telomir Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
CytoMed Therapeutics	$250K	53.47	-$3.10M	N/A	N/A

CytoMed Therapeutics' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
CytoMed Therapeutics	N/A	N/A	N/A

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CytoMed Therapeutics beats Telomir Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Lite Strategy?

CytoMed Therapeutics (NASDAQ:GDTC) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

In the previous week, CytoMed Therapeutics and CytoMed Therapeutics both had 1 articles in the media. CytoMed Therapeutics' average media sentiment score of 0.75 beat Lite Strategy's score of 0.00 indicating that CytoMed Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lite Strategy	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CytoMed Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the broader market. Comparatively, Lite Strategy has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Lite Strategy shares are owned by institutional investors. 1.6% of Lite Strategy shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CytoMed Therapeutics' return on equity of 0.00% beat Lite Strategy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytoMed Therapeutics	N/A	N/A	N/A
Lite Strategy	N/A	-90.81%	-89.33%

CytoMed Therapeutics has higher earnings, but lower revenue than Lite Strategy.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoMed Therapeutics	$250K	53.47	-$3.10M	N/A	N/A
Lite Strategy	$65.30M	0.56	-$15.94M	-$1.60	N/A

Summary

CytoMed Therapeutics beats Lite Strategy on 5 of the 9 factors compared between the two stocks.

Get CytoMed Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GDTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GDTC vs. The Competition

Export

Metric	CytoMed Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.37M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	N/A	18.74	20.99	25.66
Price / Sales	53.47	323.98	560.30	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	2.51	7.09	10.41	7.14
Net Income	-$3.10M	$24.45M	$3.57B	$335.98M
7 Day Performance	-6.61%	6.38%	6.41%	4.15%
1 Month Performance	18.86%	2.43%	3.55%	2.54%
1 Year Performance	-48.75%	62.98%	34.12%	35.06%

CytoMed Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GDTC CytoMed Therapeutics	0.4932 of 5 stars	$1.13 flat	N/A	-48.8%	$13.37M	$250K	N/A	N/A	Gap Up
INMB INmune Bio	1.398 of 5 stars	$1.66 -1.4%	$8.00 +383.1%	-80.1%	$44.02M	$50K	N/A	10
ELUT Elutia	2.6233 of 5 stars	$1.02 -1.9%	$6.00 +488.2%	-32.6%	$43.64M	$12.29M	1.24	180	Gap Up
ATOS Atossa Genetics	2.528 of 5 stars	$5.03 -2.3%	$36.33 +622.3%	-60.2%	$43.36M	N/A	N/A	8
TELO Telomir Pharmaceuticals	1.4406 of 5 stars	$1.26 -0.8%	N/A	-38.6%	$43.32M	N/A	N/A	1	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GDTC) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytoMed Therapeutics (GDTC) Competitors

GDTC vs. INMB, ELUT, ATOS, TELO, and LITS

How does CytoMed Therapeutics compare to INmune Bio?

Summary

How does CytoMed Therapeutics compare to Elutia?

Summary

How does CytoMed Therapeutics compare to Atossa Genetics?

Summary

How does CytoMed Therapeutics compare to Telomir Pharmaceuticals?

Summary

How does CytoMed Therapeutics compare to Lite Strategy?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC vs. The Competition

CytoMed Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytoMed Therapeutics (GDTC) Competitors

GDTC vs. INMB, ELUT, ATOS, TELO, and LITS

How does CytoMed Therapeutics compare to INmune Bio?

Do analysts prefer GDTC or INMB?

Do institutionals and insiders have more ownership in GDTC or INMB?

Does the media favor GDTC or INMB?

Which has more risk & volatility, GDTC or INMB?

Which has higher valuation & earnings, GDTC or INMB?

Is GDTC or INMB more profitable?

Summary

How does CytoMed Therapeutics compare to Elutia?

Does the media refer more to GDTC or ELUT?

Do insiders and institutionals have more ownership in GDTC or ELUT?

Do analysts rate GDTC or ELUT?

Which has stronger earnings & valuation, GDTC or ELUT?

Is GDTC or ELUT more profitable?

Which has more volatility and risk, GDTC or ELUT?

Summary

How does CytoMed Therapeutics compare to Atossa Genetics?

Which has more risk and volatility, ATOS or GDTC?

Do analysts prefer ATOS or GDTC?

Which has higher earnings & valuation, ATOS or GDTC?

Does the media prefer ATOS or GDTC?

Is ATOS or GDTC more profitable?

Do institutionals & insiders have more ownership in ATOS or GDTC?

Summary

How does CytoMed Therapeutics compare to Telomir Pharmaceuticals?

Does the media prefer TELO or GDTC?

Which has more volatility and risk, TELO or GDTC?

Which has preferable valuation & earnings, TELO or GDTC?

Is TELO or GDTC more profitable?

Do institutionals and insiders hold more shares of TELO or GDTC?

Do analysts prefer TELO or GDTC?

Summary

How does CytoMed Therapeutics compare to Lite Strategy?

Does the media favor GDTC or LITS?

Do analysts recommend GDTC or LITS?

Which has more volatility and risk, GDTC or LITS?

Do institutionals & insiders believe in GDTC or LITS?

Is GDTC or LITS more profitable?

Which has better valuation and earnings, GDTC or LITS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC vs. The Competition

CytoMed Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools